Brelar 60 mg (Ticagrelor)

Adult dosage

This drug should not be used concomitantly with other ADP receptor inhibitors (ticlopidine, clopidogrel, prasugrel). Acute coronary syndrome: Administer an initial dose of 180 mg, followed by 90 mg twice daily. Treatment is recommended for 12 months unless discontinuation is clinically necessary. Patients taking this drug should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. Patients with a history of myocardial infarction (occurring at least 1 year previously) and at high risk of thrombotic cardiovascular events: Administer 60 mg twice daily. Patients taking this drug should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. Patients who took this drug 90 mg or another ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel) during the first year after myocardial infarction may continue treatment with this drug at 60 mg. Treatment with this drug may also be initiated in patients within 2 years after myocardial infarction or within 1 year after discontinuing a previous ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel). The safety and efficacy of this drug were evaluated at 3 years of follow-up. Patients with type 2 diabetes who have undergone percutaneous coronary intervention (PCI) for coronary artery disease: Administer 60 mg twice daily. Patients taking this drug should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. Refer to the dosage and administration for patients with acute coronary syndrome. Data on the safety and efficacy of this drug for treatment exceeding 3 years are limited. Patients with acute ischemic stroke or high-risk transient ischemic attack: Administer an initial dose of 180 mg, followed by 90 mg twice daily for 30 days. Patients taking this drug should also receive a maintenance dose of aspirin (75 - 100mg), unless specifically contraindicated. An initial loading dose of aspirin (300-325mg) is recommended in patients with acute ischemic stroke or high-risk transient ischemic attack. This drug is administered orally and may be taken with or without food. Patients who have difficulty swallowing tablets should crush this drug into a fine powder, disperse it in half a glass of water, and drink the mixture immediately, then rinse the glass used with half a glass of water and drink it again. This mixture may also be administered through a nasogastric tube (CH8 or larger); it is important to flush the tube with water after administration. When switching from another antiplatelet agent to this drug, start this drug 24 hours after the last dose of the previous medication. If a dose is missed, take only 1 tablet (the next scheduled dose) at the next scheduled dosing time. No dose adjustment is necessary in patients with renal impairment. No dose adjustment is necessary in patients with mild hepatic impairment. This drug has not been studied in patients with severe hepatic impairment, and experience with its use in patients with moderate hepatic impairment is limited.

Children's dosage

The safety and efficacy of this drug have not been established in pediatric patients under 18 years of age (see “Other” section).

This medication inhibits the aggregation of platelets in the blood to prevent clot formation. However, the risk of bleeding may increase, so it should not be used in patients with active pathological bleeding or a history of intracranial hemorrhage. It is advisable to discontinue this medication at least 5 days prior to surgery. If bleeding symptoms occur, inform healthcare providers immediately and it is important to treat the bleeding if possible without stopping the medication. This medication should not be administered to patients with allergies to its components or severe liver dysfunction, or when used in conjunction with certain strong medications. Use with caution in patients at high risk of bleeding, as well as those with recent trauma, surgery, or coagulopathy. Special caution is warranted when used with non-steroidal anti-inflammatory drugs, oral anticoagulants, or high-dose aspirin due to an increased risk of bleeding. Notify your physician or dentist in advance if surgery is planned, and discontinue the medication 5 days prior. Patients with risks of arrhythmias such as bradycardia or atrioventricular block should be monitored closely, especially if taking this medication alongside drugs that may induce bradycardia. Patients with asthma or chronic obstructive pulmonary disease should be particularly cautious as they may experience shortness of breath; if symptoms are severe, discontinue use. Patients suspected of having central sleep apnea may need further evaluation. For patients with a history of ischemic stroke, this medication should only be used for up to 1 year, and use thereafter is not recommended. Patients aged 75 years and older, those with moderate to severe renal impairment, and those taking specific antihypertensive medications should undergo regular kidney function tests. Patients with a history of hyperuricemia or gout should take this medication cautiously; if preventative treatment is needed, it should not be administered. This medication can interact with several drugs; therefore, always consult healthcare providers if taking other medications. Use caution when driving or operating machinery as dizziness or confusion may occur. Use during pregnancy is not recommended, and women of childbearing age should avoid becoming pregnant while taking this medication. If breastfeeding, consider discontinuing either breastfeeding or the medication, as this drug may be excreted in breast milk. Safety and efficacy in children under 18 years have not been established, hence its use is not recommended. In case of overdose, the risk of bleeding increases, so notify healthcare providers immediately for appropriate treatment. This medication should be stored out of reach of children and in its original container.

• Hemorrhage
• intracranial hemorrhage
• ocular hemorrhage
• ear hemorrhage
• hypotension
• respiratory distress
• respiratory tract hemorrhage
• gastrointestinal hemorrhage
• diarrhea
• nausea

This medication should be stored in a tightly closed container to prevent exposure to air and moisture. A storage temperature between 1 degree and 30 degrees Celsius is recommended for maintaining the drug's efficacy and safety.

Appearance

Pink, biconvex, round film-coated tablets.

Package unit

30 tablets - 10 tablets/TPP[x3], 60 tablets - 10 tablets/TPP[x6]